Open access · CC-BY
via OpenAlex
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile
Clinical and Translational Medicine · 2026 · ▲ 5 citations
Abstract
BACKGROUND: Clonal haematopoiesis (CH) is an age-related condition increasingly recognised for its relevance in haematologic malignancies. In chronic lymphocytic leukaemia (CLL), its prevalence and clinical implications are gaining attention, particularly in the context of prolonged patient survival and the widespread adoption of targeted therapies. A comprehensive understanding of the biological and clinical significance of CH in CLL is therefore essential. METHODS: This review synthesises current evidence on the biological basis, epidemiology and clinical impact of CH in CLL. Data from prospective clinical trials, real-world cohorts and translational studies were analysed to explore the associations between CH, genomic instability, immune dysregulation and inflammaging(definition). Particular attention was given to the interaction between CH and contemporary therapeutic strategies, including Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors, and their potential influence on long-term outcomes. RESULTS: Available evidence indicates that CH is relatively frequent in patients with CLL and may contribute to disease biology through mechanisms involving genomic instability, chronic inflammation and immune system alterations. Emerging data suggest that CH can influence prognosis, treatment-related toxicities and cardiovascular risk, as well as predispose to therapy-related myeloid neoplasms. The interplay between CH and targeted agents may further modulate long-term outcomes, although the impact of CH on Richter transformation remains incompletely defined. CONCLUSIONS: CH represents a clinically relevant factor in the management of CLL in the era of targeted therapies. Its detection may have important implications for risk stratification, toxicity monitoring and survivorship care. Further prospective studies are needed to clarify its prognostic value and to integrate CH assessment into routine clinical practice and personalised treatment algorithms. KEY POINTS: Clonal haematopoiesis (CH) is common in patients with chronic lymphocytic leukaemia (CLL) and reflects age-related genomic and inflammatory remodeling of haematopoiesis. CH may influence prognosis, treatment-related toxicities, cardiovascular risk, and the development of therapy-related myeloid neoplasms. Targeted therapies, including BTK and BCL2 inhibitors, interact differently with CH compared with chemoimmunotherapy, potentially mitigating some adverse effects. Integrating CH assessment into CLL management may improve risk stratification and long-term survivorship strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ctm2.70633
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Martino, E.A., Caserta, S., Skafi, M., Alvaro, M.E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Vigna, E., Morabito, F., & Gentile, M. (2026). Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. <em>Clinical and Translational Medicine</em>. https://doi.org/10.1002/ctm2.70633
Vancouver
Martino EA, Caserta S, Skafi M, Alvaro ME, Bruzzese A, Amodio N, et al. Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70633.
BibTeX
@article{enrica2026Clonal,
title = {Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy},
author = {Enrica Antonia Martino and Santino Caserta and Mamdouh Skafi and Maria Eugenia Alvaro and Antonella Bruzzese and Nicola Amodio and Eugenio Lucia and Virginia Olivito and Caterina Labanca and Francesco Mendicino and Ernesto Vigna and Fortunato Morabito and Massimo Gentile},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70633},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nutrients 2026
Open access · CC-BY
Intermittent Fasting: A Metabolically Focused Therapeutic Strategy for Obesity
Atherosclerosis 2026
Open access · OA
Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions
Journal of Veterinary Science 2025
Open access · CC-BY
Aging biology and geriatric disease in dogs and cats
Immunological investigations 2026
Citation only
Pharmacological Modulation of Immunosenescence and Inflammaging: Senolytics, Senomorphics, and Emerging Therapies.
Immunological Investigations 2026
Citation only
Pharmacological Modulation of Immunosenescence and Inflammaging: Senolytics, Senomorphics, and Emerging Therapies
Progress in Neurobiology 2017
Citation only